Gibot, Sébastien http://orcid.org/0000-0001-6067-4662
Lafon, Thomas
Jacquin, Laurent
Lefevre, Benjamin
Kimmoun, Antoine
Guillaumot, Anne
Losser, Marie-Reine
Douplat, Marion
Argaud, Laurent
De Ciancio, Guillaume
Jolly, Lucie
Touly, Nina
Derive, Marc
Malaplate, Catherine
Luc, Amandine
Baumann, Cédric
François, Bruno
Funding for this research was provided by:
Bpifrance
Article History
Received: 21 April 2023
Accepted: 5 July 2023
First Online: 14 August 2023
Declarations
:
: Written informed consent was obtained from the patient or his legal representative before enrolment. The study was conducted following the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council for Harmonization. The study was approved by Comité de Protection des Personnes Est III.
: Not applicable.
: Sébastien Gibot is a co-founder of Inotrem, a company that develops TREM-1 inhibitors. Lucie Jolly, Nina Touly, and Marc Derive are employees of Inotrem. Bruno François is consultant for Inotrem. Other authors have no competing interests.